Pancreatic tumor lysate (PANC-1) (PANC-1 lysate)

Tumor-associated antigens within PANC-1/pancreatic tumor lysate refer to the total protein content derived from the PANC-1 human pancreatic ductal adenocarcinoma cell line, used primarily as an immunogenic source for cancer vaccines (ATCC, 2023). This lysate contains a broad spectrum of antigens, including well-known markers like mesothelin, carcinoembryonic antigen (CEA), and mucin 1 (MUC1), which are overexpressed in pancreatic cancer (NIH, 2022). In therapeutic applications, the lysate is typically used to pulse dendritic cells, which then present these antigens to the patient's immune system to elicit a multi-antigenic, polyclonal T-cell response (PubMed, PMID: 24510240). This approach is designed to minimize the risk of tumor escape that often occurs with single-antigen targeting. However, because the lysate is a complex mixture of both tumor-specific and normal cellular proteins, it is not considered a single molecular target but rather a substrate for immunotherapy. The use of whole-cell lysates in clinical trials aims to improve outcomes in pancreatic cancer, a disease characterized by a dense stroma and poor immune infiltration (StatPearls, 2023).

Other names

PANC-1 tumor cell lysatePANC1 lysatePancreatic cancer cell lysateWhole tumor cell lysate (PANC-1)Tumor-associated antigens (TAAs) from PANC-1

The lysate serves as a source of multiple tumor-associated antigens (TAAs) that are captured and processed by antigen-presenting cells (APCs), such as dendritic cells. These APCs then present the resulting peptides via MHC class I and II molecules to prime and activate a broad, polyclonal T-cell response (CD8+ and CD4+) against the tumor (PubMed, PMID: 24510240).